

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

The effect of consuming farmed salmon compared to salmon oil capsules on long chain omega 3 fatty acid and selenium status in humans

A thesis presented in partial fulfilment of the requirements for the degree of
Masters of Science in Human Nutrition
Institute of Food, Nutrition and Human Health
At Massey University, Auckland,
New Zealand.

Melanie Pauga

June 2009

ABSTRACT

Salmon is a good source of long chain (LC) omega 3 fatty acids and selenium; these are well recognised for their health benefits. Recommendations for LC omega 3 fatty acid intakes presume equivalence between fish and fish oil. The aim of this research was to compare the effects of consuming salmon with salmon oil capsules on LC omega 3 fatty acid and selenium status.

Forty four healthy subjects were randomly assigned to consume either two servings of 120 g farmed New Zealand King (FNZK) salmon/week or 2, 4 or 6 capsules of salmon oil/day for 8 weeks. Fasting blood samples, anthropometric measures, food consumption habits information and blood pressure (BP) measurements were obtained at the study commencement and ending.

Each subject's intake of LC omega 3 fatty acids and selenium was determined by analysing the fatty acid and selenium content of duplicate portions of cooked salmon and capsules. The amount of salmon consumed was then calculated by subtracting unconsumed amounts of salmon and then calculating the intake of LC omega 3 fatty acids as grams of LC omega 3 fatty acids consumed per day. Percentage of compliance to capsule intake, based on counts of unconsumed capsules, was calculated to determine the amount of LC omega 3 fatty acids consumed per day from capsules. Change in red blood cells (RBC) LC omega 3 fatty acid levels from equivalent amounts of LC omega 3 fatty acids consumed from capsules and salmon were compared using linear regression analysis predictive models fitted to the capsule data. Omega 3 index was calculated.

LC omega 3 fatty acid intakes from salmon and 2, 4 and 6 capsules were 0.82, 0.24, 0.47 and 0.68 g/day, respectively. Equal amounts of LC omega 3 fatty acids consumed from salmon and capsules resulted in similar increases in RBC LC omega 3 fatty acids and omega 3 index (RBC eicosapentaenoic acid (EPA): 0.80 [0.58 – 1.02] vs. 1.00 [0.71 – 1.27] %; RBC docosahexaenoic acid (DHA): 0.93 [0.58 – 1.29] vs. 0.99 [0.68 – 1.31] %; omega 3 index: 1.92 [1.46 – 2.38] vs. 2.25 [1.65 – 2.83] %). The capsules did not contain selenium, but the salmon provided 6.84 µg selenium/day. Plasma selenium concentrations increased significantly in the salmon group compared to the capsule

group (0.16 ± 0.13 vs. 0.02 ± 0.13 $\mu\text{mol/l}$). Whole blood glutathione peroxidase (GPx) did not change with either treatment.

Salmon and capsules were equally effective in increasing RBC LC omega 3 fatty acid levels and omega 3 index. Consuming salmon also increased plasma selenium concentrations. Thus, omega 3 fatty acid status can be improved by either method according to consumer preference; however salmon has the added benefit of increasing plasma selenium status.

ACKNOWLEDGEMENTS

This thesis was completed with the help and support of several people without which it could not have been achieved.

Firstly, I would like to thank the 42 subjects that participated in the study for taking the time and loyally remaining on the treatment for the duration of the study.

Secondly, I would like to thank my research supervisors, Associate Professor Welma Stonehouse and Dr Rozanne Kruger, for their knowledge and guidance. Also special thanks to help from Dr Marie Wong and Yan Wang.

Finally, I would like to thank my family, particularly my parents, for their help and support. Especially for allowing me time to complete this work, for listening to me when I needed it and reading over work when I needed a second opinion.

TABLE OF CONTENTS

ABSTRACT.....	I
ACKNOWLEDGEMENTS	III
LISTS OF TABLES.....	VII
LISTS OF FIGURES	IX
LIST OF ABBREVIATIONS.....	X
CHAPTER 1	1
1. INTRODUCTION.....	1
1.1 PURPOSE OF THE STUDY.....	4
1.1.1 AIM.....	4
1.1.2 OBJECTIVES.....	4
1.1.2.1 PRIMARY OBJECTIVES.....	4
1.1.2.2 SECONDARY OBJECTIVES.....	4
1.1.3 HYPOTHESIS	5
1.1.4 STRUCTURE OF THE THESIS	5
CHAPTER 2	7
2. LITERATURE REVIEW.....	7
2.1 OMEGA 3 FATTY ACIDS.....	7
2.1.1 OMEGA 3 FATTY ACIDS: CLASSIFICATION AND CHEMISTRY.....	7
2.1.2 OMEGA 3 FATTY ACIDS: METABOLISM	11
2.1.3 OMEGA 3 FATTY ACIDS: FOOD SOURCES.....	15
2.1.4 OMEGA 3 FATTY ACIDS: RECOMMENDATIONS FOR INTAKE	17
2.1.5 OMEGA 3 FATTY ACIDS: BIOMARKERS.....	20
2.1.6 OMEGA 3 FATTY ACIDS: STATUS IN NEW ZEALAND.....	25
2.1.6.1 Omega 3 fatty acid status in New Zealand: Dietary Intakes.....	25
2.1.6.2 Omega 3 fatty acid status in New Zealand: Tissue Levels	27
2.2 INCREASING OMEGA 3 FATTY ACID STATUS: FOOD VS. SUPPLEMENTS.....	30
2.2.1 INCREASING OMEGA 3 FATTY ACID STATUS: BIOAVAILABILITY FROM FISH VS. FISH OIL	30
2.2.2 INCREASING OMEGA 3 FATTY ACID STATUS: FOOD - SALMON.....	34
2.2.2.1 Food- Salmon: Nutrient Composition.....	36
2.2.2.2 Food- Salmon: Contaminants Present.....	38
2.2.2.3 Food- Salmon: Factors Influencing Omega 3 Fatty Acid Content	39
2.2.2.4 Food- Salmon: Cost	41
2.2.3 INCREASING OMEGA 3 FATTY ACID STATUS: SUPPLEMENT- FISH OIL	42
2.2.3.1 Supplement- Fish Oil: Fat Oxidation	42
2.2.3.1.1 Fat Oxidation: Peroxide Value.....	44
2.2.3.1.2 Fat Oxidation: Anisidine Value	45
2.2.3.2 Supplement- Fish Oil: Tolerance to Fish Oil.....	45
2.2.3.3 Supplement- Fish Oil: Cost.....	47
2.2.4 INCREASING OMEGA 3 FATTY ACID STATUS: SUMMARY	48
2.3 OMEGA 3 FATTY ACIDS & DISEASE PREVENTION.....	49
2.3.1 INTRODUCTION	49
2.3.2 OMEGA 3 FATTY ACIDS & DISEASE PREVENTION: CVD STUDIES	50
2.3.2.1 Omega 3 Fatty Acids and CVD Studies: Meta-analysis	52
2.3.2.2 Omega 3 Fatty Acids and CVD Studies: Observational Studies	56
2.3.2.3 Omega 3 Fatty Acids and CVD Studies: Randomised Controlled Trial.....	58

2.3.2.4	Omega 3 Fatty Acids and CVD Studies: Biomarker Studies.....	60
2.3.2.4.1	Biomarker Studies: Lipid Profile	60
2.3.2.4.2	Biomarkers: Blood Pressure.....	62
2.4	OMEGA 3 INDEX	64
2.5	SELENIUM	67
2.5.1	SELENIUM: FOOD SOURCES.....	68
2.5.2	SELENIUM : INCREASING STATUS	69
2.5.3	SELENIUM: BIOMARKERS.....	70
2.5.4	SELENIUM: RECOMMENDATIONS FOR INTAKES	71
2.5.5	SELENIUM: DISEASE PREVENTION.....	72
2.5.6	SELENIUM: STATUS IN NEW ZEALAND.....	74
2.5.7	SELENIUM: SUMMARY	76
CHAPTER 3	77
3.	METHODS	77
3.1	FUNDING AND ETHICS APPROVAL	77
3.2	SUBJECTS	77
3.2.1	INCLUSION/EXCLUSION CRITERIA	77
3.2.2	SUBJECT RECRUITMENT	77
3.3	SETTING AND PROCEDURES.....	78
3.3.1	STUDY DESIGN AND METHODS	79
3.3.2	INTERVENTION.....	80
3.3.2.1	SALMON.....	80
3.3.2.2	CAPSULES.....	81
3.3.3	TREATMENT TOLERANCE.....	82
3.3.4	FOOD CONSUMPTION HABITS.....	83
3.3.4.1	Calculation of Number of Servings Consumed	83
3.3.5	ANTHROPOMETRY.....	85
3.3.6	BLOOD PRESSURE	86
3.3.7	BLOOD SAMPLE	86
3.4	BIOCHEMICAL ANALYSIS.....	87
3.4.1	RED BLOOD CELL FATTY ACIDS.....	87
3.4.2	OMEGA 3 INDEX.....	88
3.4.3	SELENIUM STATUS.....	88
3.4.4	PLASMA LIPID PROFILE	89
3.4.5	SELENIUM CONTENT IN SALMON AND CAPSULES	89
3.4.6	OXIDATION VALUE OF CAPSULES.....	89
3.4.6.1	Anisidine Value.....	90
3.4.6.2	Peroxide Value	90
3.4.7	FATTY ACID ANALYSIS OF SALMON AND CAPSULES	92
3.4.7.1	Oil Extraction from Salmon.....	92
3.4.7.2	Fatty Acid Analysis of Salmon and Capsules.....	93
3.5	DATA HANDLING AND ANALYSIS.....	95
CHAPTER 4	97
4.	RESULTS	97
4.1	SUBJECT CHARACTERISTICS.....	97
4.1.1	ANTHROPOMETRIC MEASURES.....	99
4.2	TREATMENTS	100
4.2.1	FATTY ACID AND SELENIUM COMPOSITION OF TREATMENTS	100
4.2.2	OXIDATION VALUES OF CAPSULES	101
4.2.3	OMEGA 3 FATTY ACID AND SELENIUM INTAKES FROM THE TREATMENTS ...	102

4.3	RED BLOOD CELL OMEGA 3 FATTY ACIDS.....	103
4.3.1	RED BLOOD CELL EPA.....	103
4.3.2	RED BLOOD CELL DHA.....	105
4.3.3	OMEGA 3 INDEX.....	107
4.4	PLASMA SELENIUM AND WHOLE BLOOD GLUTATHIONE PEROXIDASE.....	109
4.5	LIPID PROFILE.....	110
4.6	BLOOD PRESSURE.....	111
4.7	TOLERANCE OF TREATMENT.....	111
4.8	FOOD CONSUMPTION HABITS.....	114
4.8.1	Consumption of foods containing Omega 3 fatty acids.....	116
4.8.2	Selenium Consumption.....	118
CHAPTER 5.....		119
5	DISCUSSION.....	119
5.1	SUBJECT CHARACTERISTICS.....	119
5.1.1	ANTHROPOMETRIC MEASURES.....	121
5.2	TREATMENTS.....	121
5.2.1	FATTY ACIDS COMPOSITION OF TREATMENTS.....	121
5.2.2	OXIDATION VALUE OF CAPSULES.....	125
5.2.3	SELENIUM INTAKE FROM TREATMENTS.....	125
5.3	RED BLOOD CELL OMEGA 3 FATTY ACIDS.....	126
5.3.1	RED BLOOD CELL EPA AND DHA.....	126
5.3.2	OMEGA 3 INDEX.....	128
5.4	PLASMA SELENIUM AND WHOLE BLOOD GLUTATHIONE PEROXIDASE.....	129
5.5	LIPID PROFILE.....	130
5.6	BLOOD PRESSURE.....	131
5.7	TOLERANCE OF TREATMENT.....	131
5.8	FOOD CONSUMPTION HABITS.....	132
CHAPTER 6.....		134
6.1	SUMMARY.....	134
6.2	CONCLUSION.....	137
6.3	STRENGTH OF THE PRESENT STUDY.....	138
6.4	LIMITATIONS TO THE PRESENT STUDY.....	139
6.5	RECOMMENDATIONS FOR FUTURE STUDIES.....	140
REFERENCES.....		141
APPENDIX.....		155
APPENDIX A: FLYERS AND BROCHURES.....		155
APPENDIX B: NORTH SHORE TIMES ADVERTISEMENT.....		156
APPENDIX C: INFORMATION SHEET.....		157
APPENDIX D: SCREENING QUESTIONNAIRE.....		161
APPENDIX E. APPOINTMENT SHEET.....		164
APPENDIX F: COMPLIANCE BOOKLETS.....		165
APPENDIX F1: COMPLIANCE BOOKLET - SALMON.....		165
APPENDIX F2: COMPLIANCE BOOKLET - CAPSULE.....		171
APPENDIX G. TOLERANCE QUESTIONNAIRE.....		176
APPENDIX H. FOOD FREQUENCY QUESTIONNAIRE.....		179

LISTS OF TABLES

Table 1. New Zealand food sources of alpha-linolenic acid.....	15
Table 2. New Zealand food sources of long chain omega 3 fatty acids	16
Table 3. Nutrient reference values for long chain omega 3 fatty acids for the Australian and New Zealand population	17
Table 4. International recommendations for long chain omega 3 fatty acids	18
Table 5. Typical omega 3 fatty acid composition in adult human tissues	20
Table 6. Fatty acid composition from low and medium fat diets	21
Table 7. Frequency of fish and seafood intake for the New Zealand population	27
Table 8. Long chain omega 3 polyunsaturated fatty acid composition of serum lipids for the New Zealand population as influenced by age	28
Table 9. Long chain omega 3 polyunsaturated fatty acid composition of serum lipids for the New Zealand population as influenced by gender	29
Table 10. Omega 3 fatty acid content of various species of wild and farmed salmon ...	34
Table 11. The typical vitamin and mineral composition of salmon and recommended daily intakes for Australia and New Zealand	37
Table 12. Common contaminants in Atlantic salmon and their potential effect on humans	39
Table 13. Total oxidation value of fish oil supplements	44
Table 14. Pregnant versus postpartum subjects who experienced adverse events from omega 3 fatty acid supplements	46
Table 15. Selected fish oil supplements on the market in New Zealand	47
Table 16. Potential benefits and issues from consumption of salmon versus capsules ..	48
Table 17. Summary of evidence for effects of consumption of fish or fish oil on cardiovascular outcomes	52
Table 18. Selected meta-analysis/reviews on the effect of omega 3 fatty acids on cardiovascular disease	55
Table 19. Selected prospective observational studies on the effect of fish consumption on cardiovascular disease	57
Table 20. Selected randomised controlled trials on the effect of omega 3 fatty acids on cardiovascular disease	59
Table 21. Effects of eicosapentaenoic acid and docosahexaenoic acid on biomarkers related to cardiovascular disease	60
Table 22. Omega 3 index as a potential risk marker	65
Table 23. Contribution of selected food groups to the total dietary selenium intake of New Zealand children	69
Table 24. Estimates of requirements for dietary selenium and plasma selenium concentrations for adequate bodily function	72
Table 25. Plasma selenium concentration of adult residents of New Zealand	75

Table 26. Calculation of the number of servings per week of milk and bread consume	84
Table 27. Calculation of the number of servings per week of foods high in omega 3 fatty acids and selenium consumed	84
Table 28. Categorisation of fish based on fat content	85
Table 29. Testing methods for plasma lipid profile	89
Table 30. Baseline characteristics of subjects	98
Table 31. Anthropometric measures	99
Table 32. Fatty acid composition and selenium content of salmon and capsules	100
Table 33. Omega 3 fatty acid and selenium intakes from the treatments based on chemical analysis	102
Table 34. Selenium status of subjects	109
Table 35. Plasma lipid profile	110
Table 36. Blood pressure	111
Table 37. Recommendations made by subjects for consuming capsules	113
Table 38. Intakes of main food categories expressed as servings per week	114
Table 39. Intakes of foods containing omega 3 fatty acids	116
Table 40. Intake of Brazil nuts	118
Table 41. Baseline red blood cell long chain omega 3 fatty acids from studies comparing the effects of fish and fish oil capsules	120
Table 42. Studies comparing the effects of consuming fish with omega 3 fatty acid supplements on long chain omega 3 fatty acid status	124

LISTS OF FIGURES

Figure 1. Biological roles of fatty acids	8
Figure 2. Classification of fat	9
Figure 3. Chemical structure of omega 3 fatty acids	10
Figure 4. Omega 3 fatty acid membrane interaction	12
Figure 5. Desaturation, elongation and retroconversion of polyunsaturated fatty acids.	13
Figure 6. Schema of potential dose responses and time courses for altering clinical events of physiologic effects of eicosapentaenoic acid and docosahexaenoic acid intake	19
Figure 7. Cross-study analysis of fatty acid levels (g/100g of total fatty acids)	24
Figure 8. Percentage of energy consumed from long chain omega 3 fatty acids	26
Figure 9. Oxidation of fat	43
Figure 10. Tissue composition of long chain omega 3 fatty acids and cardiovascular mortality	51
Figure 11. Summary of the overall mean percentage changes in lipids and lipoproteins in fish oil trials according to lipid disorder.....	62
Figure 12. Summary of evidence for the proposed ranges of omega 3 index with greatest and least cardio-protection	66
Figure 13. Structure of selenoproteins: selenomethionine and selenocysteine.....	67
Figure 14. Study design	79
Figure 15. p-Anisidine value of the capsule oil during the study	101
Figure 16. Peroxide value of the capsule oil during the study.....	101
Figure 17. Change in red blood cell eicosapentaenoic acid levels in different treatment groups	103
Figure 18. Predictive model of change in red blood cell eicosapentaenoic acid concentration from capsules compared to eicosapentaenoic acid from salmon	104
Figure 19. Change in red blood cell docoahexaenoic acid concentration in different treatment groups	105
Figure 20. Predictive model of change in red blood cell docoahexaenoic acid concentration from capsules compared to docoahexaenoic acid from salmon	106
Figure 21. Omega 3 index at the baseline and end of the study.....	107
Figure 22. Predictive model of omega 3 index from capsules compared to omega 3 fatty acids from salmon.....	108
Figure 23. Reporting of side effects from treatment.....	112

LIST OF ABBREVIATIONS

Δ	end value – baseline value
AA	arachidonic acid
AI	adequate intake
ALA	α -linolenic acid
B	baseline value
BMI	body mass index
BP	blood pressure
CHD	coronary heart disease
CVD	cardiovascular disease
DART	diet and reinfarction trial
DART 2	diet and angina randomised trial
DHA	docosahexaenoic acid
DPA	docosapentaenoic acid
E	end value
EAR	estimated average requirement
EPA	eicosapentaenoic acid
FAME	fatty acids methyl esters
FFQ	food frequency questionnaire
FNZK salmon	farmed New Zealand King salmon
FSANZ	food standard Australia New Zealand
GC	gas chromatography
GISSI	gruppo Italiano per la sperimentazione della streptochinasi nell'Infarto miocardico
GPx	glutathione peroxidase
HDL-C	high density lipoprotein cholesterol
JELIS	Japan eicosapentaenoic acid lipid intervention study
LA	linoleic acid
LC	long chain
LDL-C	low density lipoprotein cholesterol
MI	myocardial infarction
MUFA	monounsaturated fatty acids
PUFA	polyunsaturated fatty acids
RBC	red blood cell
RCT	randomised controlled trial
RDI	recommended daily intake
SDT	suggested dietary target
SFA	saturated fatty acids
TC	total cholesterol
TC:HDL-C	total cholesterol to high density lipoprotein cholesterol ratio
TG	triacylglycerols
UL	upper level of intake
VLDL-C	very low density lipoprotein cholesterol
waist:hip	waist circumference to hip circumference ratio